Balance Sheet
Cash Flow Statement
Capital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashDeferred TaxesDepreciation & Amortization (CF)Depreciation and DepletionDivestmentsExchange Rate EffectFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresLong-Term Debt RepaymentsNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesOther financing activitiesShare-based CompensationShares Repurchased
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Oramed Pharmaceuticals (ORMP) Change in Account Payables (2023 - 2024)

Oramed Pharmaceuticals (ORMP) has disclosed Change in Account Payables for 2 consecutive years, with $1.5 million as the latest value for Q3 2024.

  • For the quarter ending Q3 2024, Change in Account Payables fell 10.42% year-over-year to $1.5 million, compared with a TTM value of $2.5 million through Sep 2024, changed N/A, and an annual FY2023 reading of -$2.2 million, down 491.76% over the prior year.
  • Change in Account Payables was $1.5 million for Q3 2024 at Oramed Pharmaceuticals, down from $2.2 million in the prior quarter.
  • Across five years, Change in Account Payables topped out at $2.2 million in Q2 2024 and bottomed at -$3.2 million in Q2 2023.